−0.5017USD
−35.32 MUSD
775.30 KUSD
60.56 M
About VolitionRX Limited
Sector
Industry
CEO
Cameron John Reynolds
Website
Headquarters
Henderson
Employees (FY)
110
Founded
1998
ISIN
US9286611077
FIGI
BBG000BQWFH2
VolitionRX Ltd. engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluids. The company was founded on September 24, 1998 and is headquartered in Henderson, NV.
VNRX Short?Hey everyone,
the price is falling into the triangle, which usually means it leaves in the same direction. The overall trend is downwards. The MA also tells to sell. What you fundamentally sea is your thing, for me it's a sell!
Volition RX - Positive News required to escape the bearcountryTo shorten things and to keep it simple: According to fibunacci should the stock stabilise at around 3.7$ and higher to keep above the 61.8 retracement.
If the company will publish some good news soon, it could be the signal for an entry.
Entryprice above 3.69$
PENNY STOCKS: VolitionRX Ltd - RUN ON ITthis one is ready for playing around
MACD near to 0.4
RSI near to 70
BULLISH
Q3 can be a good timing
$VNRX on watchlist for breakout VolitionRX Ltd. is a multi-national life sciences company. It engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was
$VNRX Prepping For A Breakout$VNRX has popped on our radar. $VNRX is trading above its 20, 50, and 200 day moving averages. A breakout to new highs above $3.63 sets $VNRX up for a nice move.
Yesterday, the company put out some news.
AUSTIN, Texas, July 18, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Voliti
Bad fundamentals good technicals for VNRXDespite reported second quarter loss of $2.9 million that did not meet Wall street expectations, VNRX (VolitionRX) might look quite bullish in a distant future. Three weeks ago there was a bullish engulfing at the bottom of a enormous rectangle which should imply some bullish momentum. This is why w
DTI8 Patrones: Cuña abajoSe puede apreciar el patron y segun las bandas de bollinger y el RSI todavia no se deberia romper el patron ya que no presenta grandes variaciones en su volatilidad y no se encuentra ni sobrecomprado ni sobrevendido
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of VNRX is 0.6160 USD — it has decreased by 0.19% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on AMEX exchange VolitionRX Limited stocks are traded under the ticker VNRX.
VolitionRX Limited is going to release the next earnings report on May 8, 2024. Keep track of upcoming events with our Earnings Calendar.
VNRX stock is 14.04% volatile and has beta coefficient of 0.31. Check out the list of the most volatile stocks — is VolitionRX Limited there?
One year price forecast for VolitionRX Limited has a max estimate of 4.5000 USD and a min estimate of 2.5000 USD.
VNRX earnings for the last quarter are −0.11 USD per share, whereas the estimation was −0.13 USD resulting in a 14.06% surprise. The estimated earnings for the next quarter are −0.10 USD per share. See more details about VolitionRX Limited earnings.
VolitionRX Limited revenue for the last quarter amounts to 165.21 K USD despite the estimated figure of 356.60 K USD. In the next quarter revenue is expected to reach 466.67 K USD.
Yes, you can track VolitionRX Limited financials in yearly and quarterly reports right on TradingView.
VNRX stock has fallen by 13.24% compared to the previous week, the month change is a 28.37% fall, over the last year VolitionRX Limited has showed a 60.76% decrease.
VNRX net income for the last quarter is −8.70 M USD, while the quarter before that showed −8.37 M USD of net income which accounts for −3.92% change. Track more VolitionRX Limited financial stats to get the full picture.
Today VolitionRX Limited has the market capitalization of 50.65 M, it has decreased by 5.81% over the last week.
No, VNRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, VNRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VolitionRX Limited stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 110.00 employees. See our rating of the largest employees — is VolitionRX Limited on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VolitionRX Limited technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VolitionRX Limited stock shows the sell signal. See more of VolitionRX Limited technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on VolitionRX Limited future price: according to them, VNRX price has a max estimate of 4.50 USD and a min estimate of 2.50 USD. Read a more detailed VolitionRX Limited forecast: see what analysts think of VolitionRX Limited and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VolitionRX Limited EBITDA is −34.58 M USD, and current EBITDA margin is −4.46 K%. See more stats in VolitionRX Limited financial statements.